Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial

Osteoporosis

A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol

NIHR Open Res

Bullock L, Nicholls E, Cherrington A, Butler-Walley S, Clark EM, Fleming J, Leyland S, Bentley I, Thomas S, Iglesias-Urrutia CP, Webb D, Smith J, Bathers S, Lewis S, Clifford A, Siciliano M, Protheroe J, Ryan S, Lefroy J, Dale N, Hawarden A, Connacher S, Horne R, O'Neill TW, Mallen CD, Jinks C, Paskins Z

doi: 10.3310/nihropenres.13571.1

Further Publications Rheumatology

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Ann Rheum Dis

Talarico R, Italiano N, Emmi G, Piga M, Cantarini L, Mattioli I, Floris A, Gentileschi S, Di Cianni F, Urban ML, Chiara E, Marinello D, Del Bianco A, Figus M, Posarelli C, Fabiani C, Vagnani S, Andreozzi G, Lorenzoni V, Turchetti G, Cauli A, Emmi L, Salvarani C, Della Casa Alberighi O, Bombardieri S, Mosca M

doi: 10.1136/ard-2024-226113

Further Publications Immunology

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Lancet Infect Dis

Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC, PANORAMIC Trial Collaborative Group

doi: 10.1016/S1473-3099(24)00431-6

Further Publications Immunology

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Lancet

Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE, VIVID Study Group

doi: 10.1016/S0140-6736(24)01762-8

Further Publications Immunology

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Lancet

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie, Nordic Lymphoma Group, Australasian Leukaemia and Lymphoma Group

doi: 10.1016/S0140-6736(24)01315-1

Further Publications Rheumatology

The influence of intervention fidelity on treatment effect estimates in clinical trials of complex interventions: A meta-epidemiological study

J Clin Epidemiol

Páez A, Nunan D, McCulloch P, Beard D

doi: 10.1016/j.jclinepi.2024.111610

Further Publications Dermatology

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Lancet

Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC

doi: 10.1016/S0140-6736(24)00101-6

Further Publications Rheumatology

Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study)

Ann Rheum Dis

Pers YM, Soler-Rich R, Vadalà G, Ferreira R, Duflos C, Picot MC, Herman F, Broussous S, Sánchez A, Noriega D, Ardura F, Alberca Zaballos M, García V, Gordillo Cano V, González-Vallinas M, Denaro V, Russo F, Guicheux J, Vilanova J, Orozco L, Meisel HJ, Alfonso M, Rannou F, Maugars Y, Berenbaum F, Barry FP, Tarte K, Louis-Plence P, Ferreira-Dos-Santos G, García-Sancho J, Jorgensen C, RESPINE consortium

doi: 10.1136/ard-2024-225771

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Related content

A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

The influence of intervention fidelity on treatment effect estimates in clinical trials of complex interventions: A meta-epidemiological study

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study)

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial